At UC San Diego, chemist Neal K. Devaraj has spent nearly two decades studying tetrazines—quick-reacting molecules that perform chemistry like a molecular key unlocking doors—and now he's solved a problem that could transform how we treat cancer. Most potent drugs like chemotherapy are indiscriminate assassins, killing cancer cells and healthy cells with equal ferocity. But Devaraj's lab has developed TRACE (tetrazine release and activation by cellular enzymes), a tool that locks these molecular keys inside cages, only releasing them when a cell-specific enzyme appears—turning chemistry into a precision instrument.
The breakthrough matters because drugs work best when they hit exactly what they're supposed to hit. Current tetrazine-based therapies, already used in human clinical trials, can trigger reactions across multiple cell types in the body, leading to off-target damage and limiting where they can safely be used. Devaraj's innovation flips this problem. By encasing tetrazines in molecular cages that remain sealed until encountering a particular enzyme, the chemistry only activates in diseased cells like tumors—cells that overexpress that specific enzyme—while leaving healthy tissue untouched.
The team tested their approach using doxorubicin (DOX), a potent cancer drug with severe clinical limitations due to its high toxicity. When the caged tetrazines encountered the target enzyme, DOX was released and deployed precisely where needed. The comparison was striking: the drug only activated at its intended destination, not in healthy cells. To push precision even further, the researchers employed a competing tetrazine-reactive scavenger to suppress any stray activation outside target cells, essentially programming the chemistry to work in a single cell type.
"What we've shown is that you can, essentially, program the chemistry in specific cell types," Devaraj, the Murray Goodman Endowed Chair in Chemistry and Biochemistry, explained in the university's announcement. "You want this to work in a cell type that's overexpressing a particular enzyme, like a cancer cell, but not in other cells—that's what we've figured out."
The applications extend beyond drug delivery. Devaraj's team built fluorescent probes that only light up after TRACE activation, creating powerful diagnostic tools. They demonstrated that cells expressing both the target enzyme and a molecular tag glowed with fluorescence—enabling real-time visualization. Another probe successfully labeled cells with high alkaline phosphatase (ALP) activity, a marker often elevated in certain tumors, lighting up only where the enzyme was active on cell surfaces.
The research appears in Nature Chemical Biology, adding to the legacy Devaraj helped establish in 2008 when he and Joseph M. Fox independently reported tetrazine coupling for bioorthogonal chemistry—introducing one of the fastest bioorthogonal reactions available. Today, tetrazines appear in labs worldwide and in clinical trials, but this new caged version represents a fundamental leap in control.
As Devaraj's lab continues refining the system to improve selectivity, the implications ripple outward: more effective drugs with fewer side effects, cleaner diagnostic imaging, and a path toward treatments that truly know the difference between disease and health.